Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients

European Heart Journal

Volumn 29, Issue 22, 2008, Pages 2742-2750

  Kushwaha, Sudhir S ^a   Raichlin, Eugenia ^a   Sheinin, Yuri ^a   Kremers, Walter K ^a   Chandrasekaran, Krishnaswamy ^a   Brunn, Gregory J ^a   Platt, Jeffrey L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cardiac transplantation; Left ventricular hypertrophy; Remodeling; Sirolimus

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CELL DIFFERENTIATION; CELL GROWTH; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

CALCINEURIN; FEMALE; HEART TRANSPLANTATION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; PROTEIN KINASES; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 56449128027     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn407     Document Type: Article

References (48)

1. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591-603.
2. Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, de Lemos JA, Drazner MH. Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension 2007;49:1385-1391.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
4. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
5. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002;105:85-92.
6. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-1462.
7. Goodroe R, Bonnema DD, Lunsford S, Anderson P, Ryan-Baille B, Uber W, Ikonomidis J, Crumbley AJ, VanBakel A, Zile MR, Pereira N. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant 2007;26:145-151.
8. Aziz TM, Burgess MI, Haselton PS, Yonan NA, Hutchinson IV. Transforming growth factor beta and diastolic left ventricular dysfunction after heart transplantation: echocardiographic and histologic evidence. J Heart Lung Transplant 2003;22:663-673.
9. Stetson SJ, Perez-Verdia A, Mazur W, Farmer JA, Koerner MM, Weilbaecher DG, Entman ML, Quinones MA, Noon GP, Torre-Amione G. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-alpha. Circulation 2001;104:676-681.
10. Peura JL, Zile MR, Feldman DS, VanBakel AB, McClure C, Uber W, Haynes H, Pereira NL. Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients. J Heart Lung Transplant 2005;24:1969-1972.
11. Julien J, Farge D, Kreft-Jais C, Guyene TT, Plouin PF, Houssin D, Carpentier A, Corvol P. Cyclosporine-induced stimulation of the renin-angiotensin system after liver and heart transplantation. Transplantation 1993;56:885-891.
12. Hannan RD, Jenkins A, Jenkins AK, Brandenburger Y. Cardiac hypertrophy: a matter of translation. Clin Exp Pharmacol Physiol 2003;30:517- 527.
13. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
14. Molkentin JD, Dorn IG II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001;63:391-426.
15. Wang X, Proud CG. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda) 2006;21:362-369.
16. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-732.
17. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-855.
18. Poolman RA, Li JM, Durand B, Brooks G. Altered expression of cell cycle proteins and prolonged duration of cardiac myocyte hyperplasia in p27KIP1 knockout mice. Circ Res 1999;85:117-127.
19. Proud CG. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004;63:403-413.
20. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, Izumo S. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003;107:1664-1670.
21. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004;109:3050-3055.
22. Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005;24:2129-2136.
23. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
24. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992;20:1251-1260.
25. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W, Shanewise JS, Solomon SD, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Eur J Echocardiogr 2006;7:79-108.
26. Dubin J, Wallerson DC, Cody RJ, Devereux RB. Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J 1990;120:116-123.
27. Quinones MA, Waggoner AD, Reduto LA, Nelson JG, Young JB, Winters WL Jr, Ribeiro LG, Miller RR. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981;64:744-753.
28. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788-1794.
29. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272:877-880.
30. Kawamata S, Sakaida H, Hori T, Maeda M, Uchiyama T. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood 1998;91:561-569.
31. Drazner MH. The transition from hypertrophy to failure: how certain are we? Circulation 2005;112:936-938.
32. Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart 2007;93:59-64.
33. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007;49:198-207.
34. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996;58:373-395.
35. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995;92:835-841.
36. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, Diamond PM, Marra MA, Gersh BJ, Wiebers DO, Petty GW, Seward JB. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 2001;76:467-475.
37. Gudmundsson GS, Smull DL, Pisani BA, Bane CD, Mendez JC, Mullen GM, Jacobs WR. Increase in atrial size in long-term survivors of heart transplant. J Am Soc Echocardiogr 2003;16:1043-1048.
38. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002;90:1284- 1289.
39. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol 1996;271:H2183-H2189.
40. Leri A, Kajstura J, Anversa P. Myocyte proliferation and ventricular remodeling. J Card Fail 2002;8(Suppl. 6):S518-S525.
41. McGill CJ, Brooks G. Cell cycle control mechanisms and their role in cardiac growth. Cardiovasc Res 1995;30:557-569.
42. Brooks G, Poolman RA, Li JM. Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. Cardiovasc Res 1998;39:301-311.
43. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994;79:487-496.
44. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-720.
45. Hauck L, Harms C, Rohne J, Gertz K, Dietz R, Endres M, von Harsdorf R. Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat Med 2008;14:315-324.
46. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007;6:304-312.
47. Kitsis RN, Peng CF, Cuervo AM. Eat your heart out. Nat Med 2007;13:539-541.
48. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M, Omiya S, Mizote I, Matsumura Y, Asahi M, Nishida K, Hori M, Mizushima N, Otsu K. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007;13:619-624.